SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...
Transcatheter aortic valve replacement (TAVR) devices continue to make a splash in the world of medical technology, with the Sapien 3 by Edwards Lifesciences Corp. leading the way. Results of the ...
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
Edwards Lifesciences gains FDA approval for Triformis Resilia, the first surgical valve for tricuspid disease, potentially ...
Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...
Edwards LifesciencesEW stock surged Friday after the medtech giant hiked its 2025 outlook following a key setback for rival Boston ScientificEW. In May, Boston Sci pulled its transcatheter aortic ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results